Simulations Plus, Inc. (NASDAQ:SLP) Given Consensus Rating of “Hold” by Brokerages

Shares of Simulations Plus, Inc. (NASDAQ:SLP) have earned a consensus rating of “Hold” from the eleven analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $25.00.

SLP has been the subject of a number of research reports. Citigroup reissued a “market perform” rating on shares of Simulations Plus in a report on Tuesday, January 6th. BTIG Research downgraded shares of Simulations Plus from a “buy” rating to a “neutral” rating in a research note on Thursday, December 18th. Zacks Research raised shares of Simulations Plus from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Simulations Plus in a report on Wednesday, October 8th. Finally, TD Cowen raised their price objective on Simulations Plus from $16.00 to $19.00 and gave the company a “hold” rating in a report on Thursday, January 8th.

Simulations Plus Price Performance

Shares of SLP opened at $20.33 on Friday. The firm has a 50 day simple moving average of $18.52 and a two-hundred day simple moving average of $16.34. The company has a market cap of $409.59 million, a P/E ratio of -6.35 and a beta of 1.09. Simulations Plus has a one year low of $12.39 and a one year high of $37.67.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Thursday, January 8th. The technology company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.05). Simulations Plus had a positive return on equity of 14.02% and a negative net margin of 81.66%.The business had revenue of $18.42 million for the quarter, compared to analyst estimates of $18.05 million. During the same period last year, the firm posted $0.17 EPS. On average, analysts expect that Simulations Plus will post 1.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Simulations Plus by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company’s stock worth $233,000 after acquiring an additional 390 shares during the last quarter. Prudential Financial Inc. raised its stake in shares of Simulations Plus by 5.7% during the second quarter. Prudential Financial Inc. now owns 17,213 shares of the technology company’s stock valued at $300,000 after acquiring an additional 930 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Simulations Plus by 3.8% during the second quarter. Invesco Ltd. now owns 36,452 shares of the technology company’s stock worth $636,000 after purchasing an additional 1,323 shares during the period. Rhumbline Advisers grew its stake in shares of Simulations Plus by 2.1% in the first quarter. Rhumbline Advisers now owns 66,222 shares of the technology company’s stock worth $1,624,000 after purchasing an additional 1,334 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Simulations Plus in the second quarter worth $25,000. Institutional investors and hedge funds own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.